Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Under the name "Project TAME", he produced the XA cigarette using palladium. However, in 1978, his project was terminated. Since 1950, the average nicotine and tar content of cigarettes has steadily fallen. Research has shown that the fall in overall nicotine content has led to smokers inhaling larger volumes of smoke per puff.
N-Acetylcysteine amide (abbrev. NACA, AD4 and also known as acetylcysteinamide) is an amide derivative of N-acetylcysteine (NAC) that appears to have better blood–brain barrier permeability and bioavailability possessing potential antioxidant and anti-inflammatory activity When administered, NACA increases glutathione levels. Glutathione neutralizes reactive oxygen species, reduces oxidative stress, and prevents induced cell damage and apoptosis. NACA has increased lipophilicity and membrane permeability compared to NAC.
The National Commission on Terrorist Attacks Upon the United States, popularly known as the 9/11 Commission, chaired by Thomas Kean, was formed in late 2002 to prepare a thorough account of the circumstances surrounding the attacks, including preparedness for and the immediate response to the attacks. The commission issued the 9/11 Commission Report in July 2004, a 585-page report based on its investigations. The report detailed the events leading up to the attacks, concluding that they were carried out by al-Qaeda. The commission also examined how security and intelligence agencies were inadequately coordinated to prevent the attacks. According to the report, "We believe the 9/11 attacks revealed four kinds of failures: in imagination, policy, capabilities, and management." The commission made numerous recommendations on how to prevent future attacks, and in 2011 was dismayed that several of its recommendations had yet to be implemented.
Sources: en.wikipedia.org
Federal level policies include Healthy, Hunger-Free Kids Act, the Supplemental Nutrition Assistance Program Education program, and Safe Routes to School funding. (PMC) The Healthy, Hunger-Free Kids Act of 2010 helped provide nutrition standards for meals and drinks through a variety of programs affecting 50 million children daily at 99,000 schools. The risk of obesity declines each year for children in poverty. The results suggest that the Healthy, Hunger-Free Kids Act's science-based nutritional standards should be maintained to support healthy growth, especially among children living in poverty, according to Health Affairs. The Supplemental Nutrition Assistance Program Education program (SNAP-Ed) is an approach that helps people be healthy and active. This program teaches people how to manage their SNAP dollars, how to shop and cook for healthy food, and how to stay active. They partner with state and local organizations to meet people where they are located. Some of their efforts include nutrition education classes, policy improvement, social media campaigns, and more. SNAP-Ed directly and sustainably improves food security either with or without food assistance. Nutrition education is critical to improving food security in the U.S. low-income population. Safe Routes to School is an initiative that makes it safe and convenient for children to walk and bicycle to and from school. The goal is to get more children to improve kids' safety, increase their health and physical activity, and to get more children walking and bicycling to school.
The Importance of Iron – From IronTherapy.Org Interactive material on Iron Metabolism Archived 2016-05-29 at the Wayback Machine – From IronAtlas.com Approach to chronic anemia : https://ashpublications.org/hematology/article/2012/1/183/83845/How-to-approach-chronic-anemia Handout: Iron Deficiency Anemia – From the National Anemia Action Council NPS News 70: Iron deficiency anaemia: NPS – Better choices, Better health – From the National Prescribing Service
Retailers report a 0.5% increase in sales during July, fuelled largely by Euro 2024 and summer discounts. 2024 United Kingdom riots: Two men who the prosecution said were part of a "baying mob" that attacked a car containing three Romanian men in Hull on 3 August are sentenced to prison terms of six years and four years eight months respectively. 17 August A large fire at Somerset House in central London is tackled by 125 firefighters. Figures show that 492 migrants crossed the English Channel in small boats, the second highest daily number since Keir Starmer became the prime minister. 18 August The Home Office announces that new plans by the UK government will see extreme misogyny treated as a form of extremism. The Courtauld Gallery at Somerset House reopens to the public following the previous day's fire, but the rest of the building remains closed. It is announced that the UK's 31 remaining Ted Baker stores will close on or by 20 August, with 500 jobs at risk. 19 August British tech tycoon Mike Lynch and his 18-year-old daughter are reported missing, along with several other people, after a yacht sinks off the coast of Sicily. Their bodies are recovered by divers over the next few days. Professor Chris Whitty, the UK's chief medical officer, meets with government ministers to discuss the UK's preparedness to respond to mpox. This follows the recent declaration of a public health emergency of international concern by the WHO.
Sources: en.wikipedia.org
== Carbon isotope discrimination == Some carboxylases, particularly RuBisCO, preferentially bind the lighter carbon stable isotope carbon-12 over the heavier carbon-13. This is known as carbon isotope discrimination and results in carbon-12 to carbon-13 ratios in the plant that are higher than in the free air. Measurement of this isotopic ratio is important in the evaluation of water use efficiency in plants, and also in assessing the possible or likely sources of carbon in global carbon cycle studies.
== Neuroendocrine tumors (209–209) == 209 Neuroendocrine tumors 209.0 Malignant carcinoid tumors of the small intestine 209.1 Malignant carcinoid tumors of the appendix, large intestine, and rectum 209.2 Malignant carcinoid tumors of other and unspecified sites 209.3 Malignant poorly differentiated neuroendocrine carcinoma 209.4 Benign carcinoid tumors of the small intestine 209.5 Benign carcinoid tumors of the appendix, large intestine, and rectum 209.6 Benign carcinoid tumors of other and unspecified sites
with TA the total concentration of species A. Note that it is customary to omit the ionic charges when writing and using these equations. When the equilibrium constants are known and the total concentrations are specified there are two equations in two unknown "free concentrations" [A] and [H]. This follows from the fact that [HA] = β1[A] [H], [H2A] = β2[A] [H]2 and [OH] = Kw[H]−1
== Etymology == The name "chordate" comes from the first of these synapomorphies, the notochord, which plays a significant role in chordate body plan structuring and movements. Chordates are bilaterally symmetric, possess a coelom and a closed circulatory system, and exhibit metameric segmentation. Although the name Chordata is attributed to William Bateson (1885), it was already in prevalent use by 1880. Ernst Haeckel described a taxon comprising tunicates, cephalochordates, and vertebrates in 1866. Though he used the German vernacular form, it is allowed under the ICZN Code because of its subsequent Latinization.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.